Effects of bisoprolol on heart rate variability in heart failure

The American Journal of Cardiology
F PoussetJ Y Le Heuzey

Abstract

Analysis of heart rate variability (HRV) provides a non-invasive index of autonomic nervous system activity. HRV has been shown to be reduced in heart failure. Preliminary data indicate that beta blockers improve clinical status in patients with heart failure, but HRV improvement remains to be demonstrated. Fifty-four patients from the randomized double-blind, placebo-controlled Cardiac Insufficiency Bisoprolol Study were included in the HRV study. The bisoprolol daily dose was 5 mg once daily. We assessed HRV during 24-hour Holter recordings before randomization and after 2 months of treatment. HRV as measured in the time domain by root-mean-square successive differences (rMSSD), the percentage of adjacent RR differences >50 ms (pNN50), and the SD of RR intervals (SDNN), and in the frequency domain by high-frequency (0.16 to 0.40 Hz) and low-frequency (0.04 to 0.15 Hz) power. Most patients were in New York Heart Association functional class III. The mean left ventricular ejection fraction was 27 +/- 7%, and heart failure was idiopathic or ischemic. After 2 months, the patients receiving bisoprolol had a reduced mean heart rate compared with that in placebo patients (p=0.0004). Bisoprolol increased 24-hour rMSSD (p=0.04) and 24...Continue Reading

References

Aug 1, 1991·Circulation·A MallianiS Cerutti
Sep 1, 1991·The American Journal of Cardiology·R E KleigerJ L Fleiss
Feb 11, 1991·Journal of the American College of Cardiology·J R CookL M Rolnitzky
Nov 15, 1989·The American Journal of Cardiology·G CasoloC Gori
Oct 14, 1971·The New England Journal of Medicine·D L EckbergE Braunwald
Jun 1, 1993·The American Journal of Cardiology·H MølgaardM Møller

❮ Previous
Next ❯

Citations

Nov 4, 2000·Journal of Cardiovascular Electrophysiology·D Aronson, A J Burger
Jan 27, 2005·QJM : Monthly Journal of the Association of Physicians·M J ReedP S Addison
Apr 27, 2002·Journal of Clinical Pharmacy and Therapeutics·H C RoutledgeJ N Townend
Dec 17, 2004·Journal of Clinical Pharmacology·Brian F McBride, C Michael White
Jun 12, 2001·International Journal of Cardiology·D Aronson, A J Burger
Jul 20, 2002·International Journal of Cardiology·Udo MeyerfeldtAlexander Schirdewan
Aug 26, 1998·Fundamental & Clinical Pharmacology·M WargonJ L Elghozi
Jan 1, 1997·Fundamental & Clinical Pharmacology·L Cloarec-Blanchard
Oct 28, 1998·Clinical Cardiology·A Stys, T Stys
Oct 7, 2010·Heart Failure Reviews·Monali Y DesaiPaul J Hauptman
Jul 4, 1998·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·B Silke, J G Riddell
May 3, 2001·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·D Aronson, A J Burger
Nov 10, 2013·International Journal of Cardiology·Hitesh C PatelCarlo di Mario
Apr 12, 2003·Obesity Research·Franco RabbiaFranco Veglio
Sep 17, 2004·Annales de cardiologie et d'angéiologie·P de GrooteC Bauters
Aug 26, 2015·Current Treatment Options in Cardiovascular Medicine·Anju Bhardwaj, Mark E Dunlap
Jul 1, 1997·Journal of the American College of Cardiology·P A HeidenreichB M Massie
Dec 31, 2002·Journal of Psychopharmacology·B SilkeD J King
May 24, 2014·Circulation Research·Viorel G Florea, Jay N Cohn
Apr 21, 2018·Clinical and Experimental Pharmacology & Physiology·Alan Pan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.